Skip to content
New issue

Have a question about this project? Sign up for a free GitHub account to open an issue and contact its maintainers and the community.

Sign up for GitHub

By clicking “Sign up for GitHub”, you agree to our terms of service and privacy statement. We’ll occasionally send you account related emails.

Already on GitHub? Sign in to your account

Jump to bottom

Update A4a.cshtml #215

Open
wants to merge 1 commit into
base: main
Choose a base branch
from
Open

Update A4a.cshtml #215

Changes from all commits
Commits
Show all changes
1 commit
Select commit
File filter

Filter by extension

Filter by extension
Conversations
Failed to load comments.
Loading
Jump to
Jump to file
Failed to load files.
Loading
Diff view
Diff view
16 changes: 8 additions & 8 deletions src/UDS.Net.Forms/Pages/UDS4/A4a.cshtml
View file
Open in desktop
Original file line number Diff line number Diff line change
Expand Up @@ -8,7 +8,7 @@

<div>
<p class="mt-1 text-sm text-gray-500">
INSTRUCTIONS: This form should be used to record treatments expected to significantly impact Alzheimer disease and related dementias (ADRD) biomarkers, whether a disease-modifying treatment that is FDA-approved for ADRD and received as part of clinical care or an investigational treatment received as part of a clinical trial. For treatments received as part of clinical care, only those that are FDA-approved for disease-modification of ADRD should be included on this form. If the participant is receiving one of these treatments as part of their clinical care at the time of clinical assessment (e.g., they are receiving lecanemab infusions), the treatment should be included on both this form and the A4 Medication form. Participation in any ADRD drug trial over an individual's lifetime should be included. If available, the ClinicalTrials.gov identifier should be entered into the "specific treatment and/or trial" cell. Information on the type of treatment can be found via ClinicalTrials.gov and is summarized in "Alzheimer's disease drug development pipeline." 1 This form should be completed by the clinician based on participant interview and/or co-participant report. For additional clarification and examples, see <guidebook kind="@Model.Visit.PACKET"></guidebook> for <strong>Form A4a</strong>. Check only <span class="underline">one</span> box per question, unless otherwise stated.
<span class="italic">INSTRUCTIONS: This form should be used to record treatments expected to significantly impact Alzheimer disease and related dementias (ADRD) biomarkers, whether a disease-modifying treatment that is FDA-approved for ADRD and received as part of clinical care or an investigational treatment received as part of a clinical trial. For treatments received as part of clinical care, only those that are FDA-approved for disease-modification of ADRD should be included on this form. If the participant is receiving one of these treatments as part of their clinical care at the time of clinical assessment (e.g., they are receiving lecanemab infusions), the treatment should be included on both this form and the A4 Medication form. Participation in any ADRD drug trial over an individual's lifetime should be included. If available, the ClinicalTrials.gov identifier should be entered into the "specific treatment and/or trial" cell. Information on the type of treatment can be found via ClinicalTrials.gov and is summarized in "</span>Alzheimer's disease drug development pipeline." 1 <span class="italic">This form should be completed by the clinician based on participant interview and/or co-participant report. For additional clarification and examples, see </span> <span class="bold"> <guidebook kind="@Model.Visit.PACKET"></guidebook> </span> for <strong>Form A4a</strong>. <span class="italic">Check only <span class="underline">one</span> box per question, unless otherwise stated.</span>
</p>
</div>

Expand All @@ -28,21 +28,21 @@
</span>
<p class="font-style: italic text-gray-500">
(If participant is exposed to more than two treatments and/or trials, use extended table below)
<p />
</p>
<thead class="bg-gray-200 border-b border-black divide-gray-100">
<tr>
<th class="px-6 py-3 text-left text-base font-semibold text-gray-900 ">
<p>Primary Drug Target </p>
<p><i class="text-gray-400">(check all that apply)</i></p>
<p><span class="text-gray-400 italic">(check all that apply)</span></p>
</th>
<th class="px-6 py-3 text-left text-base font-semibold text-gray-900">
Specific treatment and/or trial
</th>
<th class="px-6 py-3 text-left text-base font-semibold text-gray-900">
Start date <i class="text-gray-400">(month/year)</i>
Start date <span class="text-gray-400 italic">(month/year)</span>
</th>
<th class="px-6 py-3 text-left text-base font-semibold text-gray-900">
End date <i class="text-gray-400">(month/year)</i>
End date <span class="text-gray-400 italic">(month/year)</span>
</th>
<th class="px-6 py-3 text-left text-base font-semibold text-gray-900">
How was the treatment provided?
Expand Down Expand Up @@ -130,16 +130,16 @@
<tr>
<th class="px-6 py-3 text-left text-base font-semibold text-gray-900 ">
<p>Primary Drug Target </p>
<p><i class="text-gray-400">(check all that apply)</i></p>
<p><span class="text-gray-400 italic">(check all that apply)</span></p>
</th>
<th class="px-6 py-3 text-left text-base font-semibold text-gray-900">
Specific treatment and/or trial
</th>
<th class="px-6 py-3 text-left text-base font-semibold text-gray-900">
Start date <i class="text-gray-400">(month/year)</i>
Start date <span class="text-gray-400 italic">(month/year)</span>
</th>
<th class="px-6 py-3 text-left text-base font-semibold text-gray-900">
End date <i class="text-gray-400">(month/year)</i>
End date <span class="text-gray-400 italic">(month/year)</span>
</th>
<th class="px-6 py-3 text-left text-base font-semibold text-gray-900">
How was the treatment provided?
Expand Down